Coronavirus update: France reports 14,412 new cases, J&J’s vaccine shows strong immune response
|According to the latest data published by the French Health Ministry on Saturday, the number of new coronavirus cases in the country spiked by a whopping 14,412, bringing up the tally to 527,446.
Note that a daily record of 16,096 new infections was set earlier this week. France reported 39 new deaths as the total fatalities rose to 31,700.
Meanwhile, the UK recorded 6,042 new coronavirus cases and 34 deaths a day before, despite the latest activity restrictions.
The official data showed the rolling seven-day average of daily cases has surged by 54% in a week. The death toll now stands at 41,971.
Infectious disease modeling expert Professor Graham Medley, who sits on the Scientific Advisory Group for Emergencies (SAGE), said: 'At a level of 10,000 (cases) we are seeing now, means that in three or four weeks we are going to see 100 deaths a day.”
Across the Atlantic, the US Centers for Disease Control and Prevention (CDC) on Saturday reported 7,009,216 confirmed cases, an increase of 50,584 from its previous count while the death count rose by 851 to 203,180.
Bringing in some optimism amid the coronavirus resurgence globally, the US pharmaceutical giant Johnson and Johnson Inc COVID-19 vaccine trial is reported to have shown a strong immune response to the coronavirus with a single dose in the early trial stages.
The company’s potential vaccine is the fourth vaccine in the final phase of trials
Market implications
The vaccine optimism could likely be negated by the continued spike in cases across the Euro area and the UK.
The US dollar, therefore, could continue to draw haven bids starting out the Non-Farm Payrolls (NFP) week on Monday.
The US dollar index settled the week closed to nine-week highs of 94.74.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.